TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection

Permanent URI for this collectionhttps://hdl.handle.net/20.500.14365/4

Browse

Filters

20222

Settings

Author: search.filters.author.Ekinci, FerhatWoS Q: search.filters.wosQuartile.N/A

Search Results

Now showing 1 - 2 of 2
  • Article
    The Value of Inflammatory Prognostic Index in Older Patients With Hormone Receptor Positive Metastatic Breast Cancer
    (2022) Oktay, Esin; Sahin, Mustafa; Erdogan, Atike Pinar; Ozveren, Ahmet; Yilmaz, Senem; Ekinci, Ferhat; Demir, Bilgin; Goksel, Gamze
    Objectives: To search the prognostic value of an inflammation based prognostic score in older patients with hormone positive, Her2 negative metastatic breast cancer. Methods: A retrospective study of 82 female patients aged 65 years and older with hormon receptor positive, Her-2 negative metastatic breast cancer diagnosed between 2011 and 2018 was conducted with collection of clinical and laboratory data. The inflammatory prognostic index (IPI) was calculated as C-reactive protein × NLR (neutrophil/ lym- phocyte ratio)/serum albumin. Survival estimates were calculated with Kaplan-Meier method. Results: The optimal cut-off points of IPI for the stratification of OS was found to be 0,75. Based on this cutoff value, patients were categorized as IPI-high and IPI-low group. High IPI was significantly associated with advanced stage at diagnosis. (p=0.03) The mean OS was 64 months in the IPI-high group and 66.9 months in the IPI-low group. (p=0,813) In patients receiving hormonotherapy in first line treatment PFS was 34.6 months in the IPI-low group and 14.5 months in the IPI high group, and a statistically significant difference was found compared to patients who received chemo- therapy in the first line. (p=0,042). Conclusion: Measurement of systemic inflammatory response in older adults with metastatic breast cancer is reliable, available, and can be clinically incorporated into current geriatric oncology algorithms
  • Article
    Citation - Scopus: 1
    Vinorelbine Induced Serpentine Supravenous Hyperpigmentation
    (Türkiye Klinikleri, 2022) Yetut, Ahsen Duygu; Dirican, Ahmet; Çelik, Cumali; Erdogan, Atıke Pınar; Taş, Semra; Ekinci, Ferhat
    Serpentine supravenous hyperpigmentation (SSH) is a rare complexity arising from antineoplastic therapy. Vinorelbine, a\rchemotherapeutic drug that is frequently used for the treatment of breast and lung cancer, contributes to the etiology of SSH. A 54 years old\rmale patient was being treated for lung adenocarcinoma. An intravenous (IV) infusion of vinorelbine was administered in the distal dorsal vein\rof the left forearm. Erythematous hyperpigmentation at the infusion area was observed a week after the administration of the chemotherapeutic\rdrug. The initial symptoms of SSH usually appear between 1 to 15 days post IV administration of a cytotoxic drug, and it spontaneously becomes\rhyperpigmented within 1-3 weeks. However, these local reactions can be prevented by applying IV infusion for a short period (15-30\rmin) along with adequate venous irrigation (75-124 mL) instead of bolus administration. The termination of the drug can also be considered.